Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alnylam Pharmaceuticals, Inc.
Alnylam and Collaborators Publish Research on a New Class of Chemically Modified RNAi Therapeutics that Target Two Distinct Cellular Mechanisms
November 18th, 2008
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced the publication of a new study in Nature Medicine by scientists from the University of Bonn in collaboration with Alnylam. The new pioneering research documents the design and evaluation of "3p-siRNAs," a new class of RNAi therapeutics comprised of small interfering RNAs (or siRNA, the molecules that mediate RNAi) which are designed and chemically modified to activate RIG-I (retinoic acid-induced gene I, a cytoplasmic immunoreceptor which strongly induces type I interferon and NK cell responses). The study showed that a 3p-siRNA specific for the anti-apoptotic factor bcl-2 may be a highly effective...
Source: Cancer Weekly (2008-11-18)
|
